| 0.53 Data as of May 23 |  0.00 / 0.00%Today’s Change | 0.30 Today|||52-Week Range 1.25 | +15.22% Year-to-Date |
| SECTOR Non-Energy Minerals | INDUSTRY Precious Metals | MARKET CAP $24.7M |
Company Description
RepliCel Life Sciences, Inc. develops and produces an autologous cell-based procedure, which is used for the treatment of androgenetic alopecia and general hair loss in men and women. Its RepliCel technology is a natural hair cell replication technology that is minimally invasive solution for androgenetic alopecia and general hair loss. The company is currently focused on ensuring the safety and demonstrating the efficacy of RepliCel's cell-based hair regeneration procedure in humans. Its long-term goal is the development of a safe, evidence-based, minimally invasive procedure to treat various types of hair loss in men and women. RepliCel Life Sciences was founded on April 24, 1967 and is headquartered in Vancouver, Canada.
Employees
Shareholders
| Mutual fund holders | -- |
| Individual stakeholders | -- |
| Other institutional | -- |
Top Executives
| David M. Hall | President, Chief Executive Officer & Director |
| Thomas A. Kordyback | Chief Financial Officer |
| Rolf Hoffmann, MD | Director & Chief Medical Officer |
| Kevin McElwee, PhD | Chief Scientific Officer |
| Darrell Panich | Vice President-Clinical Affairs |
.
